IP Library Granted Patent US 10,710,948
Granted Patent B2
US 10,710,948 · App. 16/546,906 · Granted Jul 14, 2020

Processes for preparing (R)-1-(5-chloro-[1,1″-biphenyl] -2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1″-biphenyl]-2-yl)-2,2,2-trifluoroethanone

Inventors: Stéphane De Lombaert (Brisbane, CA); Daniel R. Goldberg (Seattle, WA)
Assignee: Roivant Sciences GmbH
C07C29/32C07C29/143C07C45/455C07C49/80C07C259/10C07B2200/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,710,948
App. No.
16/546,906
Granted
Jul 14, 2020
Kind
B2
Abstract

The present invention relates to processes for the preparation of (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol, 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone, and intermediates thereof, which are useful in the preparation of inhibitors of TPH1 for the treatment of, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, low bone mass diseases, serotonin syndrome, and cancer.

Claims (11)

1. A process of preparing a compound of Formula A:

comprising reducing a compound of Formula B:

in the presence of a chiral catalyst.

2. The process of claim 1 , wherein said chiral catalyst comprises iridium.

3. The process of claim 1 , wherein said chiral catalyst is prepared by combining dichloro(pentamethylcyclopentadienyl)iridium(III) dimer with (1R, 2R)-(−)-N-(4-toluenesulfonyl)-1,2-diphenylethylenediamine.

4. The process of claim 1 , wherein said reducing is carried out at elevated temperature.

5. The process of claim 4 , wherein said elevated temperature is about 40° C.

6. The process of claim 1 , wherein said reducing is carried out in the presence of a formate.

7. The process of claim 6 , wherein said formate is potassium formate.

8. The process of claim 1 , wherein said reducing is carried out in the presence of a solvent.

9. The process of claim 8 , wherein said solvent comprises acetonitrile.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2021
From: ROIVANT SCIENCES GMBH
To: ALTAVANT SCIENCES GMBH
Reel/Frame 055536/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2019
From: KAROS PHARMACEUTICALS
To: ROIVANT SCIENCES GMBH
Reel/Frame 050162/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2019
From: DE LOMBAERT, STÉPHANE; GOLDBERG, DANIEL R.
To: KAROS PHARMACEUTICALS
Reel/Frame 050128/0803 →
Continuity (4)
Division 15430786 · Feb 13, 2017
Division 15059627 · Mar 3, 2016
Provisional Application 62128652 · Mar 5, 2015
Related Publication 20190375699A1 · Dec 12, 2019